Products Affected - Description
All presentations are currently available
Reason for the Shortage
- American Regent discontinued benztropine injection in May 2015.
- Fresenius Kabi launched benztropine in September 2016.
Cogentin injection, Akorn
1 mg/mL, 2 mL ampule, 5 count (NDC 76478-0611-02)
Benztropine Mesylate injection, Akorn
1 mg/mL, 2 mL ampule, 5 count (NDC 17478-0012-02)
Benztropine Mesylate injection, Fresenius Kabi
1 mg/mL, 2 mL vial, 5 count (NDC 63323-0970-02)
Benztropine Mesylate injection, West-Ward
1 mg/mL, 2 mL ampule, 5 count (NDC 00143-9729-05)
Estimated Resupply Dates
All marketed presentations are available.
October 14, September 8, August 11, June 17 and 9, May 20, March 21, January 25 and 14, 2016; December 11, November 4, October 19 and 12, August 20 and 19, July 23, June 11 and 9, April 30, March 25, February 11, January 26 and 7, 2015; September 18, July 31, June 11, May 8, March 4, January 29, 2014; December 16 and 4, October 29, September 26, August 28, July 18, 2013, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins